Can I read Comparative Safety and Efficacy of Statins for Primary Prevention in Human Immunodeficiency Virus-positive Patients: a Systematic Review and Meta-analysis on EtoBox?

Comparative Safety and Efficacy of Statins for Primary Prevention in Human Immunodeficiency Virus-positive Patients: a Systematic Review and Meta-analysis by Sebastiano Gili; Walter Grosso Marra; Fabrizio D'Ascenzo; Enrica Lonni; Andrea Calcagno; Margherita Cannillo; Flavia Ballocca; Enrico Cerrato; Martina Pianelli; Umberto Barbero; Massimo Mancone; James J. DiNicolantonio; Carl J. Lavie; Pierluigi Omedè; Antonio Montefusco; Stefano Bonora; Mauro Gasparini; Giuseppe Biondi-Zoccai; Claudio Moretti; Fiorenzo Gaita is a Medicine article available to read on EtoBox.

What is Comparative Safety and Efficacy of Statins for Primary Prevention in Human Immunodeficiency Virus-positive Patients: a Systematic Review and Meta-analysis about?

The efficacy and safety of different statins for human immunodeficiency virus (HIV)-positive patients in the primary prevention setting remain to be established. In the present meta-analysis, 18 studies with 736 HIV-positive patients receiving combination antiretroviral therapy (cART) and treated with statins in the primary prevention setting were included (21.0% women, median age 44.1 years old). The primary endpoint was the effect of statin therapy on total cholesterol (TC) levels. Rosuvastatin 10 mg and atorvastatin 10 mg provided the largest reduction in TC levels [mean -1.67, 95% confidence interval (CI) (-1.99, -1.35) mmol/L; and mean -1.44, 95% CI (-1.85, -1.02) mmol/L, respectively]. Atorvastatin 80 mg and simvastatin 20 mg provided the largest reduction in low-density lipoprotein (LDL) [mean -2.10, 95% CI (-3.39, -0.81) mmol/L; and mean -1.57, 95% CI (-2.67, -0.47) mmol/L, respectively]. Pravastatin 10-20 mg [mean 0.24, 95% CI (0.10, 0.38) mmol/L] and atorvastatin 10 mg [mean 0.15, 95% CI (0.007, 0.23) mmol/L] had the largest increase in high-density lipoprotein, whereas atorvastatin 80 mg [mean -0.60, 95% CI (-1.09, -0.11) mmol/L] and simvastatin 20 mg [mean -0.61, 95% CI

Who reads Comparative Safety and Efficacy of Statins for Primary Prevention in Human Immunodeficiency Virus-positive Patients: a Systematic Review and Meta-analysis?

Author

Sebastiano Gili; Walter Grosso Marra; Fabrizio D'Ascenzo; Enrica Lonni; Andrea Calcagno; Margherita Cannillo; Flavia Ballocca; Enrico Cerrato; Martina Pianelli; Umberto Barbero; Massimo Mancone; James J. DiNicolantonio; Carl J. Lavie; Pierluigi Omedè; Antonio Montefusco; Stefano Bonora; Mauro Gasparini; Giuseppe Biondi-Zoccai; Claudio Moretti; Fiorenzo Gaita

Published

2016

Language

EN

Field

Medicine (Health Sciences)